• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Five changes healthcare executives can expect in 2018


The winds of change swept through healthcare in 2017. Here’s what 2018 could bring.

The winds of change swept through healthcare in 2017, leaving in their path more uncertainty than perhaps ever before.

With my window seat view via 40-plus leading health systems with which we work all over the country, here’s my take on what managed care executives and other industry constituents can expect:

  • Leveraging analytics.

Leveraging clinical and data analytics has been cited as the top challenge for healthcare executives.  I agree with those industry experts who expect that half of all healthcare companies will have dedicated resources to accessing, sharing and analyzing real-world evidence for use across their organizations by 2019. On top of that, I assert that the focus in 2018 will be in operational analytics that improve operational performance-not clinical outcomes. We saw an early indication of this with UCHealth; they were able to increase annual revenue from their operating rooms by more than $10 million largely by improving the method by which operating room block time is released or requested.

  • Doing more with less.

In 2018, health systems should begin to see the need to re-evaluate the mathematical foundation used to manage their day-to-day operations-and upon which the quality of the patient experience relies. All the macro forces in healthcare (more patients, older patients, higher incidence of chronic illnesses, lower reimbursements, push toward value-based care, and tighter operating and capital budgets) indicate an urgent need to be able to do more with existing assets without upsetting patient flow. A strong mathematical foundation will enable a level of operational excellence to help health systems increase their effective capacity for treating more patients while simultaneously improving the overall flow and reducing wait time.

  • Piloting blockchain-based solutions.

In 2018, more managed care execs will pilot blockchain-based solutions as a way to streamline secure medical record sharing, protect sensitive data from hackers and give patients more control over their health records. Blockchain-based solutions are already in the prototype stage and represent the first step in providing patients “with one-stop-shop access to their medical history across multiple providers.” One prototype uses blockchain technology to manage authentication, confidentiality, accountability and data sharing (data such as blood work records, vaccination history, prescriptions, and other therapeutic treatments).

  • Continuing consolidation

Last year, I predicted that the now-abandoned mega mergers of Anthem with Cigna and Aetna with Humana would usher in a period of more mergers and acquisition. The termination of both of those deals-on the same day, no less-under the cloud of antitrust seemed to dampen the market’s interest. Nonetheless, this year, I predict continued consolidation and contraction, especially in the pharmaceutical space as billions worth of patents for drugs begin to expire. Pharmaceutical companies will look closely at smaller companies, from whom the next generation of “blockbuster” drugs are just now coming to market.

  • Continuing regulatory chaos.

If 2017 taught us anything, it is this: 2018 will be another year where managed care executives, payers, providers, and pharmaceutical and life sciences organizations face continued legislative and regulatory upheaval as consumers demand more, better access. Healthcare providers will continue to feel pressure to accelerate their companies’ transformations using advanced data science and mobile technologies.

I believe those who invest in health IT ahead of the curve, focus on better utilizing the mountains of data they strain to secure and look to connect systems as never before will emerge from an uncertain year better positioned to succeed and prosper.


Sanjeev Agrawal is president and chief marketing officer of LeanTaaS, a Silicon Valley-based innovator of predictive analytics solutions to healthcare’s biggest operational challenges. 

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.